Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology...
LAUSANNE, Switzerland--(BUSINESS WIRE)--Mar 8, 2019--Galderma, Nestl Skin Health's medical solutions business, presented the final results from a Phase 2b dose-ranging study of nem…
